Excelsior Biopharma (6496) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Excelsior Biopharma (6496) has a cash flow conversion efficiency ratio of 0.004x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$3.80 Million ≈ $119.63K USD) by net assets (NT$896.79 Million ≈ $28.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Excelsior Biopharma - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Excelsior Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Excelsior Biopharma total liabilities for a breakdown of total debt and financial obligations.
Excelsior Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Excelsior Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rising Dragon Acquisition Corp. Ordinary Shares
NASDAQ:RDAC
|
-0.002x |
|
Panda Eco System Berhad
KLSE:0290
|
0.077x |
|
Farm Price Holdings Berhad
KLSE:0304
|
0.039x |
|
Kirklands Inc
NASDAQ:KIRK
|
0.190x |
|
Korea Eng Cons
KO:023350
|
-0.188x |
|
The Berkeley Group Holdings plc
LSE:BKG
|
0.041x |
|
UPA Corporation Bhd
KLSE:7757
|
0.038x |
|
Virtualware 2007 S.A.
PA:MLVIR
|
N/A |
Annual Cash Flow Conversion Efficiency for Excelsior Biopharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Excelsior Biopharma.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$991.45 Million ≈ $31.24 Million |
NT$-99.80 Million ≈ $-3.14 Million |
-0.101x | +17.50% |
| 2023-12-31 | NT$1.10 Billion ≈ $34.80 Million |
NT$-134.75 Million ≈ $-4.25 Million |
-0.122x | -2785.29% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.04 Million |
NT$5.49 Million ≈ $172.84K |
0.005x | -89.99% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.76 Million |
NT$55.82 Million ≈ $1.76 Million |
0.045x | -88.82% |
| 2020-12-31 | NT$1.28 Billion ≈ $40.42 Million |
NT$520.81 Million ≈ $16.41 Million |
0.406x | +400.08% |
| 2019-12-31 | NT$1.25 Billion ≈ $39.53 Million |
NT$-169.74 Million ≈ $-5.35 Million |
-0.135x | -246.36% |
| 2018-12-31 | NT$1.37 Billion ≈ $43.26 Million |
NT$126.92 Million ≈ $4.00 Million |
0.092x | -64.57% |
| 2017-12-31 | NT$1.34 Billion ≈ $42.21 Million |
NT$349.47 Million ≈ $11.01 Million |
0.261x | -- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more